Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 333)
Posted On: 07/08/2019 3:52:49 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Leading the Way in Effective Cannabis Treatment
- Lexaria developed and out-licenses DehydraTECH to create new (and improve existing) drug-delivery products
- The company is credited with leading the way forward in discovering new ways to effectively deliver CBD into the human body
- Lexaria is helping firms meet supply and demand requirements by creating products that offer lower dosing with higher absorption
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is known for its innovative delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. The company developed drug-delivery platform DehydraTECH and out-licenses the platform to create new (and improve existing) orally ingested products.
DehydraTECH is patented for cannabidiol and all other non-psychoactive cannabinoids, as well as for THC (tetrahydrocannabinol) and psychoactive cannabinoids. Additional patents are expected in 2019 as the company continues to investigate how it’s proprietary edible technology can enhance treatment for Parkinsons, Alzheimers, human hormone delivery, erectile dysfunction and more.
CannabisNewsWire (CNW), a multifaceted financial news and publishing company for private and public entities in the cannabis industry, ran an article titled ‘Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatment’ in which LXRP was featured (http://nnw.fm/26rZ9). CNW credited LXRP for leading the way forward for the cannabis industry in discovering new ways to more effectively deliver CBD into the human body.
The article outlined the ways that the industry has struggled to achieve higher rates of absorption. Current cannabis medicines are poorly absorbed by the body, which consequently increases cost and reduces effectiveness. Companies such as LXRP, however, are working to create better delivery systems that make CBD more accessible and improve more lives.
One of the delivery challenges is the amount of CBD waste created, because the human body can only absorb a small amount of the molecules. DehydraTECH is disrupting this cycle by protecting the product during stomach transit, amplifying intestinal absorption by five to ten times over traditional methods and enabling the drug to bypass first-pass liver metabolism. Third-party lab studies have shown a 15- to 20-minute onset of THC effects in humans when using the edible tech.
Products that use the DehydraTECH drug-delivery platform have been shown to deliver CBD faster than those that use medium-chain triglyceride oils. A recent study reported a 319 percent higher CBD blood concentration at 60 minutes when using the DehydraTECH formulation as opposed to coconut oil (http://nnw.fm/Cs2DX). Fatty acids used with DehydraTECH have the added benefit of masking the bitter taste of CBD, allowing a better overall experience for the consumer without the need for added sugars or chemicals.
According to the CNW article (http://nnw.fm/Ohz5D), the legal changes in Canada and the United States have made it so that suppliers are unable to meet the increase in demand for CBD. DehydraTECH enables the creation and enhancement of products that use smaller amounts of CBD and remain just as effective, thereby reducing production cost and providing a higher quality experience.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria developed and out-licenses DehydraTECH to create new (and improve existing) drug-delivery products
- The company is credited with leading the way forward in discovering new ways to effectively deliver CBD into the human body
- Lexaria is helping firms meet supply and demand requirements by creating products that offer lower dosing with higher absorption
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is known for its innovative delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. The company developed drug-delivery platform DehydraTECH and out-licenses the platform to create new (and improve existing) orally ingested products.
DehydraTECH is patented for cannabidiol and all other non-psychoactive cannabinoids, as well as for THC (tetrahydrocannabinol) and psychoactive cannabinoids. Additional patents are expected in 2019 as the company continues to investigate how it’s proprietary edible technology can enhance treatment for Parkinsons, Alzheimers, human hormone delivery, erectile dysfunction and more.
CannabisNewsWire (CNW), a multifaceted financial news and publishing company for private and public entities in the cannabis industry, ran an article titled ‘Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatment’ in which LXRP was featured (http://nnw.fm/26rZ9). CNW credited LXRP for leading the way forward for the cannabis industry in discovering new ways to more effectively deliver CBD into the human body.
The article outlined the ways that the industry has struggled to achieve higher rates of absorption. Current cannabis medicines are poorly absorbed by the body, which consequently increases cost and reduces effectiveness. Companies such as LXRP, however, are working to create better delivery systems that make CBD more accessible and improve more lives.
One of the delivery challenges is the amount of CBD waste created, because the human body can only absorb a small amount of the molecules. DehydraTECH is disrupting this cycle by protecting the product during stomach transit, amplifying intestinal absorption by five to ten times over traditional methods and enabling the drug to bypass first-pass liver metabolism. Third-party lab studies have shown a 15- to 20-minute onset of THC effects in humans when using the edible tech.
Products that use the DehydraTECH drug-delivery platform have been shown to deliver CBD faster than those that use medium-chain triglyceride oils. A recent study reported a 319 percent higher CBD blood concentration at 60 minutes when using the DehydraTECH formulation as opposed to coconut oil (http://nnw.fm/Cs2DX). Fatty acids used with DehydraTECH have the added benefit of masking the bitter taste of CBD, allowing a better overall experience for the consumer without the need for added sugars or chemicals.
According to the CNW article (http://nnw.fm/Ohz5D), the legal changes in Canada and the United States have made it so that suppliers are unable to meet the increase in demand for CBD. DehydraTECH enables the creation and enhancement of products that use smaller amounts of CBD and remain just as effective, thereby reducing production cost and providing a higher quality experience.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼